Approval
FDA Approves Imfinzi ADC Regimen
The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin followed by adjuvant Imfinzi after radical cystectomy for eligible adults with muscle-invasive bladder cancer. The regimen is intended for patients who are ineligible for or decline cisplatin-based chemotherapy, and the approval came six weeks ahead of the FDA's target review date. The approval was based on the phase 3 VOLGA trial, which enrolled 695 patients; its results were presented at ESMO 2026 and published in the New England Journal of Medicine.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.